Earlier this week, during its 3Q 2019 earnings call, Pfizer announced the U.S. launch dates for three of its biosimilar products:
- ZIRABEV (bevacizumab-bvzr), a biosimilar of Genentech’s AVASTIN, which received approval in June, will launch December 31, 2019. We previously posted that on September 20, 2019, Genentech and Pfizer settled their BPCIA litigation concerning Pfizer’s biosimilar product.
- RUXIENCE (rituximab-pvvr), a biosimilar of Genentech’s RITUXAN, which received approval in July, will launch in January 2020. Several sources reported that Genentech and Pfizer reached a settlement earlier this year regarding a patent for RITUXAN.
- TRAZIMERA (trastuzumab-qyyp), a biosimilar of Genentech’s HERCEPTIN, which received approval in March, will launch February 15, 2020. In December 2018, Genentech and Pfizer settled their related patent litigation.
